Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

weight-2036971_960_720

Novo Nordisk’s therapy delivers significant weight loss in trial

June 25, 2025 Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions

Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …
News

Opterion Health strengthens board with appointments of Rice Powell and Mark Hahn

June 25, 2025 Research and Development CEO, Nephrology, Opterion Health, board of directors, cfo, chronic kidney disease, dialysis solution

Swiss life sciences company Opterion Health has appointed two senior industry figures to its board of directors: Rice Powell, former …
Appointment

PLL Therapeutics appoints renowned ALS expert Philippe Corcia to scientific board

June 25, 2025 Research and Development ALS Reference Centre, National ALS Motor Neuron Study Group, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis (ALS), scientific board

PLL Therapeutics has appointed leading amyotrophic lateral sclerosis (ALS) researcher Philippe Corcia to its scientific board, marking a strategic move …
Appointment

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma

June 24, 2025 Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …
News

Neurizon confirms positive results for prospective ALS treatment

June 23, 2025 Research and Development Neurizon Therapeutics, Neurology, amyotrophic lateral sclerosis, blood-brain barrier, clinical data, neurodegenerative diseases

Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain …
News
blood-1813410_960_720

Novo Nordisk presents promising findings for haemophilia treatment

June 23, 2025 Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval

Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …
News

NICE recommends spevigo for rare and severe psoriasis flares

June 20, 2025 Medical Communications, Research and Development Dermatology, NHS, National Institute for Health and Care Excellence, generalised pustular psoriasis

The National Institute for Health and Care Excellence (NICE) has recommended Spevigo (spesolimab) for the treatment of generalised pustular psoriasis …
News

First UK patient treated with CSL Behring’s gene therapy for Haemophilia B

June 20, 2025 Research and Development CSL Behring, Haematology, NHS England, cell therapy, gene therapy, haemophilia B, prophylactic infusions

CSL Behring has announced that the first patient in the UK has received HEMGENIX (etranacogene dezaparvovec) through the NHS, marking …
News

Eyestem completes phase 1 trial of retinal cell therapy with promising vision gains

June 20, 2025 Research and Development Eyestem Research, Opthalmology, cell therapy, clinical trial, dry age-related macular degeneration, geographic atrophy

Eyestem Research has announced the successful completion of its phase 1 trial evaluating Eyecyte-RPE, an investigational cell therapy for geographic …
News
money-2180330_960_720

Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology

June 20, 2025 Freelancers, Licensing & business development, Research and Development Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer

Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research …
News

Celltrion opens new UK headquarters in Uxbridge to drive long-term growth

June 19, 2025 Research and Development Corporate, Pharmacy, biosimilar medicines, celltrion

Celltrion, focused on the development of biosimilar medicines, has officially opened its new UK headquarters in the Charter Building, Uxbridge, …
News
handshake

KFSHRC and Germfree to launch first modular ATMP manufacturing campus in Saudi Arabia

June 19, 2025 Medical Communications, Research and Development Advanced Therapy Medicinal Product manufacturing, BIO 2025, Corporate, King Faisal Specialist Hospital & Research Centre, Saudi Arabia, biotechnology development, cell therapies, gene therapies

King Faisal Specialist Hospital & Research Centre (KFSHRC) has announced a landmark partnership with Germfree Laboratories to develop Saudi Arabia’s …
News
AstraZeneca_drug_discovery

Bristol Myers Squibb to present positive new data on lymphoma treatment

June 18, 2025 Medical Communications, Research and Development Bristol Myers Squibbs, CAR T-cell therapy, International Conference on Malignant Lymphoma, Oncology, relapsed or refractory marginal zone lymphoma

Bristol Myers Squibb (BMS) has announced positive results from the TRANSCEND FL phase 2 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) …
News
lab

Captain T Cell joins Bayer Co.Lab Berlin to accelerate TCR therapies

June 18, 2025 Analytical & Laboratory Services, Business Services, Research and Development Bayer Co.Lab, Bayer Co.Lab Berlin, Captain T Cell, Corporate, T-cell receptor therapy, laboratory services

Captain T Cell, a biotech company developing next-generation T-cell receptor (TCR)-based therapies for solid tumours, has announced its selection for …
News
money_pills_2

EVerZom receives €3m funding from French government to industrialise exosome technology

June 18, 2025 Research and Development BpiFfrance, Corporate, Crohn’s disease, EVerZom, France 2030, French government, age-related disorders, exosome therapy, neurodegenerative disease

EVerZom, a French biopharma company focused on exosome-based therapies, has announced it has received €3m in funding as part of …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025